465 related articles for article (PubMed ID: 26133550)
1. Uncovering Molecular Bases Underlying Bone Morphogenetic Protein Receptor Inhibitor Selectivity.
Alsamarah A; LaCuran AE; Oelschlaeger P; Hao J; Luo Y
PLoS One; 2015; 10(7):e0132221. PubMed ID: 26133550
[TBL] [Abstract][Full Text] [Related]
2. Development of an ALK2-biased BMP type I receptor kinase inhibitor.
Mohedas AH; Xing X; Armstrong KA; Bullock AN; Cuny GD; Yu PB
ACS Chem Biol; 2013; 8(6):1291-302. PubMed ID: 23547776
[TBL] [Abstract][Full Text] [Related]
3. Structural basis for specificity of TGFβ family receptor small molecule inhibitors.
Ogunjimi AA; Zeqiraj E; Ceccarelli DF; Sicheri F; Wrana JL; David L
Cell Signal; 2012 Feb; 24(2):476-483. PubMed ID: 21983015
[TBL] [Abstract][Full Text] [Related]
4. BMP-2 and BMP-9 binding specificities with ALK-3 in aqueous solution with dynamics.
Coskuner O; Uversky VN
J Mol Graph Model; 2017 Oct; 77():181-188. PubMed ID: 28869862
[TBL] [Abstract][Full Text] [Related]
5. Design, 3D QSAR modeling and docking of TGF-β type I inhibitors to target cancer.
Ajay Kumar TV; Athavan AAS; Loganathan C; Saravanan K; Kabilan S; Parthasarathy V
Comput Biol Chem; 2018 Oct; 76():232-244. PubMed ID: 30077902
[TBL] [Abstract][Full Text] [Related]
6. Vasohibin-1 expression is regulated by transforming growth factor-β/bone morphogenic protein signaling pathway between tumor-associated macrophages and pancreatic cancer cells.
Shen Z; Seppänen H; Kauttu T; Vainionpää S; Ye Y; Wang S; Mustonen H; Puolakkainen P
J Interferon Cytokine Res; 2013 Aug; 33(8):428-33. PubMed ID: 23651239
[TBL] [Abstract][Full Text] [Related]
7. Structural basis for the potent and selective binding of LDN-212854 to the BMP receptor kinase ALK2.
Williams E; Bullock AN
Bone; 2018 Apr; 109():251-258. PubMed ID: 28918311
[TBL] [Abstract][Full Text] [Related]
8. Discovery of 3-(4-sulfamoylnaphthyl)pyrazolo[1,5-a]pyrimidines as potent and selective ALK2 inhibitors.
Jiang JK; Huang X; Shamim K; Patel PR; Lee A; Wang AQ; Nguyen K; Tawa G; Cuny GD; Yu PB; Zheng W; Xu X; Sanderson P; Huang W
Bioorg Med Chem Lett; 2018 Nov; 28(20):3356-3362. PubMed ID: 30227946
[TBL] [Abstract][Full Text] [Related]
9. Identification of the role of bone morphogenetic protein (BMP) and transforming growth factor-β (TGF-β) signaling in the trajectory of serotonergic differentiation in a rapid assay in mouse embryonic stem cells in vitro.
Yamasaki A; Kasai A; Toi A; Kurita M; Kimoto S; Hayata-Takano A; Nakazawa T; Nagayasu K; Shintani N; Hashimoto R; Ito A; Meltzer HY; Ago Y; Waschek JA; Onaka Y; Matsuda T; Baba A; Hashimoto H
J Neurochem; 2015 Feb; 132(4):418-28. PubMed ID: 25421849
[TBL] [Abstract][Full Text] [Related]
10. In vivo structure-activity relationship study of dorsomorphin analogues identifies selective VEGF and BMP inhibitors.
Hao J; Ho JN; Lewis JA; Karim KA; Daniels RN; Gentry PR; Hopkins CR; Lindsley CW; Hong CC
ACS Chem Biol; 2010 Feb; 5(2):245-53. PubMed ID: 20020776
[TBL] [Abstract][Full Text] [Related]
11. Identification of small molecule inhibitors of ALK2: a virtual screening, density functional theory, and molecular dynamics simulations study.
Kausar T; Nayeem SM
J Mol Model; 2018 Aug; 24(9):262. PubMed ID: 30159679
[TBL] [Abstract][Full Text] [Related]
12. A unique mutation of ALK2, G356D, found in a patient with fibrodysplasia ossificans progressiva is a moderately activated BMP type I receptor.
Fukuda T; Kanomata K; Nojima J; Kokabu S; Akita M; Ikebuchi K; Jimi E; Komori T; Maruki Y; Matsuoka M; Miyazono K; Nakayama K; Nanba A; Tomoda H; Okazaki Y; Ohtake A; Oda H; Owan I; Yoda T; Haga N; Furuya H; Katagiri T
Biochem Biophys Res Commun; 2008 Dec; 377(3):905-9. PubMed ID: 18952055
[TBL] [Abstract][Full Text] [Related]
13. Structure of the bone morphogenetic protein receptor ALK2 and implications for fibrodysplasia ossificans progressiva.
Chaikuad A; Alfano I; Kerr G; Sanvitale CE; Boergermann JH; Triffitt JT; von Delft F; Knapp S; Knaus P; Bullock AN
J Biol Chem; 2012 Oct; 287(44):36990-8. PubMed ID: 22977237
[TBL] [Abstract][Full Text] [Related]
14. Identification of a functional binding site for activin on the type I receptor ALK4.
Harrison CA; Gray PC; Koerber SC; Fischer W; Vale W
J Biol Chem; 2003 Jun; 278(23):21129-35. PubMed ID: 12665502
[TBL] [Abstract][Full Text] [Related]
15. 2D-QSAR study, molecular docking, and molecular dynamics simulation studies of interaction mechanism between inhibitors and transforming growth factor-beta receptor I (ALK5).
Jiang MN; Zhou XP; Sun DR; Gao H; Zheng QC; Zhang HX; Liang D
J Biomol Struct Dyn; 2018 Nov; 36(14):3705-3717. PubMed ID: 29064324
[TBL] [Abstract][Full Text] [Related]
16. Identification of 1,5-naphthyridine derivatives as a novel series of potent and selective TGF-beta type I receptor inhibitors.
Gellibert F; Woolven J; Fouchet MH; Mathews N; Goodland H; Lovegrove V; Laroze A; Nguyen VL; Sautet S; Wang R; Janson C; Smith W; Krysa G; Boullay V; De Gouville AC; Huet S; Hartley D
J Med Chem; 2004 Aug; 47(18):4494-506. PubMed ID: 15317461
[TBL] [Abstract][Full Text] [Related]
17. Crystal structure of the BMP-2-BRIA ectodomain complex.
Kirsch T; Sebald W; Dreyer MK
Nat Struct Biol; 2000 Jun; 7(6):492-6. PubMed ID: 10881198
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe.
Engers DW; Frist AY; Lindsley CW; Hong CC; Hopkins CR
Bioorg Med Chem Lett; 2013 Jun; 23(11):3248-52. PubMed ID: 23639540
[TBL] [Abstract][Full Text] [Related]
19. A new class of small molecule inhibitor of BMP signaling.
Sanvitale CE; Kerr G; Chaikuad A; Ramel MC; Mohedas AH; Reichert S; Wang Y; Triffitt JT; Cuny GD; Yu PB; Hill CS; Bullock AN
PLoS One; 2013; 8(4):e62721. PubMed ID: 23646137
[TBL] [Abstract][Full Text] [Related]
20. Bone morphogenetic proteins.
Chen D; Zhao M; Mundy GR
Growth Factors; 2004 Dec; 22(4):233-41. PubMed ID: 15621726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
